(AOF) – Theradiag posted turnover of 9.9 million euros as of September 30, 2023, up 11% year-on-year. The company specializing in the in vitro diagnosis of autoimmune diseases and Theranostic achieved a turnover of 3.2 million euros in the third quarter of 2023 compared to 2.6 million euros in the third quarter of 2022, i.e. growth of +20%, mainly supported by the In Vitro Diagnostic (IVD) activity which grew by +44%. The cash level at the end of September 2023 remains under control and reached more than 5.5 million euros.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
